Duane Snavely

5.8k total citations · 1 hit paper
38 papers, 3.4k citations indexed

About

Duane Snavely is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Duane Snavely has authored 38 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cognitive Neuroscience, 12 papers in Experimental and Cognitive Psychology and 9 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Duane Snavely's work include Sleep and related disorders (11 papers), Sleep and Wakefulness Research (11 papers) and Circadian rhythm and melatonin (8 papers). Duane Snavely is often cited by papers focused on Sleep and related disorders (11 papers), Sleep and Wakefulness Research (11 papers) and Circadian rhythm and melatonin (8 papers). Duane Snavely collaborates with scholars based in United States, Canada and United Kingdom. Duane Snavely's co-authors include Robert Segal, Bertram Pitt, Paul Chang, Alan Cowley, Ignatius Thomas, Felipe A Martinez, Prakash Deedwania, Christopher Lines, W. Joseph Herring and David Michelson and has published in prestigious journals such as The Lancet, Neurology and Biological Psychiatry.

In The Last Decade

Duane Snavely

37 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1997 1.2k citations Bertram Pitt, Robert Segal et al. The Lancet profile →

Peers

Countries citing papers authored by Duane Snavely

Since Specialization

Citations

This map shows the geographic impact of Duane Snavely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Duane Snavely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Duane Snavely more than expected).

Fields of papers citing papers by Duane Snavely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Duane Snavely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Duane Snavely. The network helps show where Duane Snavely may publish in the future.

Co-authorship network of co-authors of Duane Snavely

This figure shows the co-authorship network connecting the top 25 collaborators of Duane Snavely. A scholar is included among the top collaborators of Duane Snavely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Duane Snavely. Duane Snavely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data 2017 ·Psychopharmacology ·W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane Snavely, Ying Zhang, Jill Hutzelmann, Deborah Matzura‐Wolfe, Ruth M. Benca, Andrew D. Krystal, James K. Walsh, Christopher Lines, Thomas Roth, David Michelson	16
2	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder 2017 ·The International Journal of Neuropsychopharmacology ·Kathryn M. Connor, Paulette Ceesay, Jill Hutzelmann, Duane Snavely, Andrew D. Krystal, Madhukar H. Trivedi, Michael E. Thase, Christopher Lines, W. Joseph Herring, David Michelson	23
3	A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia 2016 ·The International Journal of Neuropsychopharmacology ·Kathryn M. Connor, Erin Mahoney, (unknown), Jill Hutzelmann, Xin Zhao, Nan Jia, Ellen Snyder, Duane Snavely, David Michelson, Thomas Roth, W. Joseph Herring	36
4	Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial 2014 ·The Lancet Neurology ·David Michelson, Ellen Snyder, (unknown), (unknown), Duane Snavely, Jill Hutzelmann, James K. Walsh, Andrew D. Krystal, Ruth M. Benca, Martin A. Cohn, Christopher Lines, Thomas Roth, W. Joseph Herring	254
5	Addition of an NK₁ receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder 2014 ·Human Psychopharmacology Clinical and Experimental ·William A. Ball, Duane Snavely, Richard Hargreaves, Armin Szegedi, Christopher Lines, Scott A. Reines	7
6	Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia 2013 ·Schizophrenia Research ·Michael Egan, Xin Zhao, (unknown), (unknown), Ying Zhang, Duane Snavely, Christopher Lines, David Michelson	42
7	Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study 2013 ·Sleep Medicine ·W. Joseph Herring, Kenneth Liu, Jill Hutzelmann, Duane Snavely, Ellen Snyder, Paulette Ceesay, Christopher Lines, David Michelson, Thomas Roth	25
8	Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia 2013 ·Human Psychopharmacology Clinical and Experimental ·Michael Egan, Xin Zhao, (unknown), Matthew D. Troyer, Victor N. Uebele, (unknown), Kevin Cox, Michael Murphy, Duane Snavely, Christopher Lines, David Michelson	32
9	Orexin receptor antagonism for treatment of insomnia 2012 ·Neurology ·W. Joseph Herring, Ellen Snyder, Kerry Budd, Jill Hutzelmann, Duane Snavely, Kenneth Liu, Christopher Lines, Thomas Roth, David Michelson	245
10	Randomized Controlled Study of the Histamine H3 Inverse Agonist MK-0249 in Adult Attention-Deficit/Hyperactivity Disorder 2012 ·The Journal of Clinical Psychiatry ·W. Joseph Herring, Timothy E. Wilens, Lenard A. Adler, Christine Baranak, Kenneth Liu, Duane Snavely, Christopher R. Lines, David Michelson	25
11	An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose‐finding study 2009 ·Statistics in Medicine ·Anastasia Ivanova, Ken Liu, Ellen Snyder, Duane Snavely	18
12	Is bigger better for depression trials? 2007 ·Journal of Psychiatric Research ·Kenneth S. Liu, Duane Snavely, William A. Ball, Christopher R. Lines, Scott A. Reines, William Z. Potter	16
13	Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder 2005 ·Biological Psychiatry ·Martin B. Keller, Stuart Montgomery, William A. Ball, Mary F. Morrison, Duane Snavely, G. Frank Liu, Richard Hargreaves, Jarmo Hietala, Christopher Lines, Katherine Beebe, Scott A. Reines	223
14	Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials 2005 ·Statistics in Medicine ·G. Frank Liu, Junyuan Wang, Kenneth Liu, Duane Snavely	56
15	Demonstration of the Efficacy and Safety of a Novel Substance P (NK1) Receptor Antagonist in Major Depression 2003 ·Neuropsychopharmacology ·Mark S. Kramer, Andrew Winokur, Jeffrey E. Kelsey, Sheldon Preskorn, Anthony J. Rothschild, Duane Snavely, Kalyan Ghosh, William A. Ball, Scott A. Reines, Dennis J. Munjack, Jeffrey Apter, Lynn Cunningham, Mitchel A. Kling, Mohammed Abdul Bari, Albert J. Getson, Yih Lee	219
16	The Cost-Effectiveness of Losartan versus Captopril in Patients with Symptomatic Heart Failure 1999 ·Cardiology ·Erik J. Dasbach, Michael W. Rich, Robert Segal, William C. Gerth, George W. Carides, J.R. Cook, James F. Murray, Duane Snavely, Bertram Pitt	17
17	Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors 1998 ·Clinical Therapeutics ·Robert Zorba Paster, Duane Snavely, (unknown), (unknown), Allan I. Goldberg, Beth A. Soffer, Charles S. Sweet	28
18	Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) breakdown → 1997 ·The Lancet ·Bertram Pitt, Robert Segal, Felipe A Martinez, (unknown), Alan Cowley, Ignatius Thomas, Prakash Deedwania, (unknown), Duane Snavely, Paul Chang	1207
19	Development and persistence of antibody in a high risk institutionalized population given plasma-derived hepatitis B vaccine 1990 ·Vaccine ·David J. West, Duane Snavely, Barbara Zając, George W. Brown, (unknown)	4
20	Ureteral fibropapilloma in a dog 1986 ·Journal of the American Veterinary Medical Association ·Arthur L. Hattel, R. W. Diters, Duane Snavely	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact